Other languages Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-17 pm EDT			5-day change	1st Jan Change
2.47 ^USD	-1.20%		0.00%	-59.84%

Feb. 27	Sector Update: Health Care Stocks Ease Late Afternoon	MT
Feb. 27	Top Midday Decliners	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Ease Late Afternoon	Feb. 27
Top Midday Decliners	Feb. 27
Sector Update: Health Care Stocks Decline Tuesday Afternoon	Feb. 27
Minerva Neurosciences Shares Tumble After FDA Rejects Roluperidone for Schizophrenia.	Feb. 27
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia	Feb. 27
Minerva Neurosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
Minerva Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-01
Sector Update: Health Care Stocks Declining Late Wednesday	23-06-28
Sector Update: Health Care	23-06-28
Top Midday Gainers	23-06-28
Minerva Neurosciences to Raise $20 Million Through Private Placement of Common Shares	23-06-28
Minerva Neurosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15
Minerva Neurosciences Says US FDA Accepts Filing of New Drug Application for Roluperidone to Treat Schizophrenia Symptoms	23-05-10
Minerva Neurosciences, Inc. Announces Board Changes	23-05-05
Top Midday Gainers	23-05-01
FDA Files Minerva Neurosciences's NDA for Roluperidone to Treat Schizophrenia Symptoms; Shares Jump 61% Midday	23-05-01
Minerva Neurosciences, Inc. Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia	23-05-01
Minerva Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Minerva Neurosciences, Inc.

Equities

NERV

US6033802058

Other languages

Filters